Ye Mingtong, Pang Nengzhi, Wan Ting, Huang Yuanling, Wei Tianyi, Jiang Xuye, Zhou Yujia, Huang Yufeng, Yang Hainan, Zhang Zhenfeng, Yang Lili
The First Women and Children's Hospital of Huizhou, Huizhou, Guangdong, PR China.
Department of Nutrition, Guangdong Provincial Key Laboratory of Food, Nutrition and Health, School of Public Health, Sun Yat-Sen University, Guangzhou, Guangdong, PR China.
J Cancer. 2019 Jan 1;10(3):757-764. doi: 10.7150/jca.28087. eCollection 2019.
Switching aerobic respiration to anaerobic glycolysis of cancer cells plays an important role in development and progression of acquired resistance. Since vitamin C enabled the inhibition of glycolysis of cancer cells, and erlotinib-resistant sub-line of HCC827 (ER6 cells) switched its metabolic features to higher glycolysis for survival, we hypothesize that vitamin C is able to inhibit glycolysis of ER6 cells. In this study, we found that both reduced vitamin C and oxidized vitamin C (DHA) could selectively suppress the viability of ER6 cells. DHA was efficient in inhibiting glycolysis and leading to energy crisis, which could be one mechanism for overcoming drug resistance to erlotinib of ER6 cells. Our data suggest that applying DHA could be a novel treatment strategy for NSCLC with acquired resistance to targeted therapy.
癌细胞从有氧呼吸转变为无氧糖酵解在获得性耐药的发展和进展中起重要作用。由于维生素C能够抑制癌细胞的糖酵解,且HCC827的厄洛替尼耐药亚系(ER6细胞)为了生存将其代谢特征转变为更高水平的糖酵解,我们推测维生素C能够抑制ER6细胞的糖酵解。在本研究中,我们发现还原型维生素C和氧化型维生素C(DHA)均可选择性抑制ER6细胞的活力。DHA在抑制糖酵解并导致能量危机方面很有效,这可能是克服ER6细胞对厄洛替尼耐药的一种机制。我们的数据表明,应用DHA可能是一种针对对靶向治疗产生获得性耐药的非小细胞肺癌的新型治疗策略。